

July 25, 2005

Shionogi & Co., Ltd.

**Shionogi Receives Approval to Manufacture and Market
Carbapenem Antibiotic Products “Finibax 0.25g IV Solution” and
“Finibax Intradermal Test” (Doripenem Hydrate)**

Shionogi & Co., Ltd. (Headquarters: Osaka, President: Motozo Shiono) received manufacturing and marketing approval on July 25 for the carbapenem antibiotic products “Finibax 0.25g IV Solution” and “Finibax Intradermal Test” (generic name: doripenem hydrate).

Finibax 0.25g IV Solution is a novel carbapenem antibiotic created by Shionogi. Shionogi has been conducting research and development with the objective of creating compounds that have both stronger antibacterial power against *Pseudomonas aeruginosa*, which is becoming a frequent problem in treating infectious diseases, and negligible effect on the central nervous system.

The usefulness of carbapenem antibiotics is already widely acknowledged, and they are used in many infectious disease treatments. However, various drug-resistant bacteria such as *Pseudomonas aeruginosa*, *Streptococcus pneumoniae* and *Hemophilus influenzae* are becoming a problem, and a more effective, safer carbapenem antibiotic has been

sought.

With the launch of Finibax 0.25g IV Solution, Shionogi will devote every effort to proper promotion to contribute further to treatment of moderate to severe infectious diseases.

Shionogi expects to launch Finibax 0.25g IV Solution by the end of September, after National Health Insurance (NHI) price listing.

For further information, contact:

Public Relations Unit

Shionogi & Co., Ltd.

(Osaka)

TEL +81-6-6209-7885 Fax +81-6-6229-9596

(Tokyo)

TEL +81-3-3406-8164 Fax +81-3-3406-8099